Defymed Company Profile

16:51 EDT 23rd March 2018 | BioPortfolio

Defymed is a spin -off of the “Centre Europeen d’etude du Diabete”  (CeeD) which has been working on the conception of a bio-artificial pancreas since 1996.

This work was carried out in tight collaboration with the “Centre de Transfert de Technologie du Mans” (CTTM) and STATICE in the frame of two research European programs: FP4 (1996-2000) and FP6 (2004-2007). This work has led to the development of a prototype of MAILPAN® medical device.

The bioartificial pancreas is believed to be the most physiological solution under development, and the one that could bring the ideal autonomy to Type 1 diabetic patients.

The strategy of encapsulation involves placing insulin-secretory cells within semi-permeable devices made of friendly and biocompatible materials. This kind of device should allow the passage of small molecules such as insulin  and glucose but prevent the entry of molecules of the immune system that could kill the encapslated cells. Thus, encapsulating these cells should prevent allograft rejection and autoimmune reaction.

  • This therapy will allow diabetes control by itself with no or reduced need of glucose monitoring and insulin delivery devices (glucose meters and associated consumables, pens, pumps)
  • This therapy is expected to allow islet transplantation with no need of immune suppressive agents. Thus the young diabetic population (<40 years old) will also have the possibility to benefit from the therapy
  • After the initial intensive follow-up period, patient medical follow-up should be reduced to routine visits every 3 to 6 months for the assessment of glucose control and iterative replacement of MAILPAN cell content, when needed
  • Acute and long-term complications of diabetes should be reduced while normal glucose control is sustained
  • The reduced burden related to diabetes care in patient daily life should allow normal work activities
  • A limited need of pancreas availability for transplants will allow treating higher number of patients



Centre Européen Étude du Diabète C.E.E.D.
Boulevard René Leriche


Phone: +33 (0)3 90 20 12 12

News Articles [1 Associated News Articles listed on BioPortfolio]

Innovative Medical Devices for the Treatment of Diabetes, Defymed Strengthens Its Position as a Worldwide Leader

French-based Medtech company Defymed confirms its global position. Recognized by its peers for the development of two innovative medical devices - ExOlin®, an insulin delivery de...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [1 Associated Companies listed on BioPortfolio]


Defymed is a spin -off of the “Centre Europeen d’etude du Diabete”  (CeeD) which has been working on the conception of a bio-artificial pancreas since 1996. This work was ca...

More Information about "Defymed" on BioPortfolio

We have published hundreds of Defymed news stories on BioPortfolio along with dozens of Defymed Clinical Trials and PubMed Articles about Defymed for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Defymed Companies in our database. You can also find out about relevant Defymed Drugs and Medications on this site too.

Quick Search


Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Medical Devices
The role of medical devices in healthcare is essential.  The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare.  Covering a wide range of products, from simple bandages to the...

Corporate Database Quicklinks

Searches Linking to this Company Record